Living network meta-analysis to compare nemolizumab against other available targeted systemic treatments for atopic dermatitis
Aaron M. Drucker, Chantel Walwyn, Cherry Chu, Zenas Z N Yiu, Bram Rochwerg, Sonya Di Giorgio, B.W.M. Arents, Tanya Mohan, Tim Burton, Phyllis I. Spuls, Jochen Schmitt, David Prieto‐Merino, Carsten Flohr
Abstract
Nemolizumab is a new biologic approved to treat atopic dermatitis. In this perspective piece, we use results from our living systematic review and network meta-analysis to provide perspective on the relative efficacy of nemolizumab compared with other approved targeted systemic treatments.
Topics & Concepts
Atopic dermatitisMedicineMeta-analysisDermatologySystemic therapyPerspective (graphical)Internal medicineComputer scienceCancerBreast cancerArtificial intelligenceDermatology and Skin DiseasesAllergic Rhinitis and SensitizationExercise and Physiological Responses